Genetic Health Labcorp’s launch of Marker by Labcorp Genetic Health Panel and its direct-to-consumer genetics capability highlights a sales opportunity to cross-sell expansive genetic testing services and integration with patient-facing health platforms.

Acquisition Expansion Recent acquisitions and asset investments in oncology testing indicate a path to upsell specialized diagnostic services, oncology-focused pipelines, and expanded testing networks to current Labcorp clients and partners.

Network Growth With over 2,200 testing facilities and a broad geographic footprint, there is potential to upsell lab services, automation, and digital tooling to enterprise accounts seeking scalable, nationwide diagnostics and data integration.

Pediatric Collaboration Joint pediatric diagnostics innovation with CHOP signals an opportunity to offer targeted pediatric testing platforms, biorepository partnerships, and co-developed assays for pediatric populations to health systems and academic partners.

Strategic Spin-off Fortrea spin-off suggests a focus shift and potential for cross-sell of contract research and clinical operations services to Labcorp’s pharmaceutical and biotech clients, leveraging existing relationships for integrated trial and testing services.